Mesenchymal Stem Cell and Islet Co-transplantation

Phase 1 Completed 3 enrolled Medical University of South Carolina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to show safety and tolerability to our mesenchymal stromal cells (MSCs) product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media (pooled human platelet lysate) and delivered fresh. Subsequently, the investigators intend to test whether infusion of MSCs immediately after islet autograft can reduce onset of diabetes and improve glycemic control after total pancreatectomy and islet autotransplantation.

Timeline

Start: 2014-12
Primary completion: 2016-06-01
Completion: 2017-11-21

Publications

Results Wang H, Strange C, Nietert PJ, Wang J, Turnbull TL, Cloud C, Owczarski S, Shuford B, Duke T, Gilkeson G, Luttrell L, Hermayer K, Fernandes J, Adams DB, Morgan KA. Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy. Stem Cells Transl Med. 2018 Jan;7(1):11-19. doi: 10.1002/sctm.17-0139. Epub 2017 Nov 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	autologous mesenchymal stromal cell	Cell therapy	2e+07 cells	Other
Subject	autologous mesenchymal stromal cell	Cell therapy	5e+07 cells	Other
Subject	autologous mesenchymal stromal cell	Cell therapy	1e+08 cells	Other

Mesenchymal Stem Cell and Islet Co-transplantation

Summary

Timeline

Publications

Drugs

Indications